Release date: 2025-04-23 10:39:20 Article From: Lucius Laos Recommended: 31
Understanding the guidelines for the use of finerenone can help to improve the rationality of the treatment process.
The initial dose of finerenone is usually 10 mg per day, but it needs to be dynamically adjusted according to the patient's renal function and serum potassium levels.
If the estimated glomerular filtration rate is less than 25 ml/min, it is recommended to reduce to 5 mg per day. If the serum potassium concentration exceeds 5.0 mmol/L during treatment, the drug should be stopped and the index changes should be monitored.
Concomitant use with potassium-sparing diuretics or renin-angiotensin system inhibitors may increase the risk of hyperkalaemia. Clinical data show that approximately 12% of patients with combination therapy have abnormally elevated serum potassium. It is recommended to have regular electrolyte levels checked and treatment adjusted if necessary.
In elderly patients over 65 years of age, the metabolic rate decreases by about 30%, and the interval between medications needs to be extended. It is contraindicated in pregnant women and has been shown to affect fetal development in animal studies. Patients with hepatic insufficiency should start with a low dose to avoid drug accumulation.
The drug has demonstrated unique advantages in specific disease areas.
Phase III clinical trials have shown that continued use of finerenone for 12 months reduces the rate of disease progression in about 37% of patients. Its mechanism of action reduces organ fibrotic damage by inhibiting mineralocorticoid receptor overactivation.
The current market price is $280-$350 per month, with some health plans covering up to 70% of the cost. Long-term use reduces hospitalization-related costs by about 45% compared to traditional treatment options.
Taking the drug at a fixed time each day can keep the blood concentration stable. There is no need to double the dose after missing a dose, and if you continue to miss a dose for more than 3 days, you should contact a medical professional. It is recommended to record changes in blood pressure and body sensation during the period of taking the drug.
Standardized use of finerenone requires a comprehensive consideration of physiological indicators, medication regimens, and individual characteristics. Regular monitoring and doctor-patient communication are important aspects of optimizing treatment outcomes, and rational medical decisions directly affect long-term prognosis.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2002024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1572025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1552025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1702024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1602024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1452024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2472024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: